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Abstract
Introduction:  Extranodal  NK/T-Cell  lymphoma,  nasal  type  (NKTLN)  is  a  disease  that  mainly
affects the  nasal  cavity  and  the  paranasal  sinuses.  Early  nasal  symptoms  are  nonspeciﬁc,
simulating  sinus  infection.  With  disease  progression,  necrosis  of  the  nasal  mucosa  increases,  hin-
dering histological  diagnosis.  Thus,  multiple  biopsies  may  be  necessary  until  deﬁnitive  diagnosis.
Most studies  on  NKTLN  address  the  hematological  and  immunological  aspects  of  the  disease.
Objectives:  To  present  data  from  a  Brazilian  quaternary  hospital,  with  emphasis  on  the  clinical
aspects of  the  disease,  and  to  correlate  the  ﬁndings  with  the  most  recent  literature  data.
Methods: Case  study  of  seven  patient  ﬁles.
Results:  Patients  were  evaluated  on  their  medical  history,  number  of  biopsies  necessary,  asso-
ciation with  Epstein--Barr  virus,  treatment,  and  outcome.  All  patients  had  nonspeciﬁc  nasal
complaints  and  underwent  at  least  three  cycles  of  antibiotic  therapy.  The  earlier  a  biopsy  was
performed,  the  fewer  biopsies  were  required  to  diagnose  the  disease  and  start  treatment.
However,  this  fact  did  not  translate  into  better  prognosis.
Conclusion:  The  otolaryngologist  plays  a  fundamental  role  in  the  prognosis  of  NKTLN  and  can
shorten time  between  symptom  onset  and  treatment  of  the  patient.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Resumo
Introduc¸ão:  O  linfoma  extranodal  de  células  NK/T  tipo  nasal  (LNKTN)  é  uma  doenc¸a  que
acomete  preferencialmente  a  cavidade  nasal  e  os  seios  paranasais.  Os  sintomas  nasais  inici-
ais são  inespecíﬁcos,  mimetizando  um  quadro  de  infecc¸ão  nasossinusal.  Com  a  progressão  da
doenc¸a, aumenta  a  necrose  da  mucosa  nasossinusal,  diﬁcultando  o  diagnóstico  histológico  e
podendo ser  necessárias  múltiplas  biópsias  até  o  diagnóstico  deﬁnitivo.  A  maioria  dos  estudos
sobre o  LNKTN  aborda  aspectos  imunológicos  e  hematológicos  da  doenc¸a.
Objetivo:  Apresentar  a  casuística  de  um  hospital  quaternário  brasileiro,  destacando  os  aspectos
clínicos dos  pacientes  e  correlacionando  aos  achados  mais  recentes  da  literatura.
Método:  Estudo  de  casos  de  sete  pacientes.
Resultados:  Pacientes  foram  avaliados  quanto  a  aspectos  de  sua  história  clínica,  número  de
biópsias necessárias,  associac¸ão  ao  EBV,  tratamento  e  evoluc¸ão.  Todos  iniciaram  o  quadro
com queixas  inespecíﬁcas  nasais  e  foram  submetidos  a  pelo  menos  três  ciclos  de  antibióti-
cos. Quanto  mais  precocemente  a  biópsia  foi  realizada,  menos  biópsias  foram  necessárias  para
se obter  o  diagnóstico  e  iniciar  o  tratamento.  Entretanto,  esta  situac¸ão  não  reﬂetiu  num  melhor
prognóstico  dos  pacientes.
Conclusão:  O  otorrinolaringologista  tem  papel  fundamental  no  prognóstico  do  LNKTN,  podendo
encurtar o  tempo  entre  o  início  dos  sintomas  e  o  tratamento  do  paciente.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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xtranodal  NK/T-Cell  lymphoma,  nasal  type  (NKTLN)  is  a
isease  that  mainly  affects  the  nasal  cavity  and  paranasal
inuses,1 and  thus,  the  otorhinolaryngologist  is  invariably
he  ﬁrst  specialist  to  evaluate  these  patients.  It  is  a  rare
isease,  more  frequent  in  middle-aged  adult  males,  with
igh  prevalence  in  East  Asia,  where  it  represents  3--10%  of
ll  malignant  tumors,  and  is  the  most  prevalent  lymphoma  in
merindian  descendants  from  South  and  Central  America.1--3
nother  factor  that  plays  an  important  role  in  the  patho-
enesis  of  the  disease  is  infection  by  the  Epstein--Barr  virus
EBV).4,5
Historically,  NKTLN  has  had  different  names.  Due  to
he  difﬁculty  in  clearly  determining  the  physiopathological
echanism  of  the  disease  in  the  past,  the  terms  ‘‘Lethal
idline  Granuloma’’  and  ‘‘Midfacial  Granuloma’’  included,
n  addition  to  NKTLN,  other  diseases  with  aggressive  evolu-
ion  that  also  affected  the  middle  portion  of  the  face,  such
s  Wegener’s  granulomatosis  and  infectious  diseases  such
s  Leishmaniasis.  The  terms  ‘‘polymorphic  reticulosis’’  and
‘angiocentric  lymphoma’’  were  attempts  to  histopatho-
ogically  characterize  NKTLN,  but  were  also  discarded,  as
hese  patterns  are  not  always  present.1,6,7 The  current  name
as  adopted  by  the  Revised  European-American  Lymphoma
lassiﬁcation  (REAL),  proposed  by  the  WHO  in  2001  and  rein-
orced  in  2008.8
In  most  cases,  the  initial  nasal  symptoms  are  unspe-
iﬁc,  such  as  rhinorrhea,  nasal  obstruction,  and  epistaxis,
imicking  a  picture  of  sinonasal  infection,  which  makes  it
ifﬁcult  to  establish  the  diagnosis  of  NKTLN.1 With  disease
rogression,  edema,  necrosis,  and  destruction  of  adjacent
tructures  occur,  which  can  cause  the  collapse  of  the  lateral
all  of  the  nasal  cavity  and  oronasal  ﬁstula.
R
TIn  patients  at  an  advanced  stage  of  the  disease,  with
bundant  necrosis  and  little  healthy  tissue,  there  is  difﬁ-
ulty  in  establishing  the  histological  diagnosis  and  multiple
iopsies  may  be  required  until  a deﬁnitive  diagnosis  is
chieved.1,9 Extra-nasal  manifestations  are  also  possible,
hich  may  be  associated  with  nasal  injury;  the  main
ffected  sites  are:  skin,  larynx,  testes,  gastrointestinal
ract,  and  kidneys.1,10 Lymphadenopathy,  either  inﬂamma-
ory  or  tumor-related,  can  also  be  observed,  especially  in
atients  with  nasal  involvement.10
Since  most  studies  available  in  the  literature  on  NKTLN
ssessed  samples  of  Asian  origin  or  have  their  primary
ocus  on  the  hematological  and  immunological  aspects,
his  study  aimed  to  assess  a  sample  from  a  Brazilian
uaternary  hospital,  highlighting  the  clinical  aspects  of
atients  and  correlating  them  to  the  most  recent  literature
ndings.
ethod
he  present  study  is  a  series  of  cases  based  on  medical
ecords  of  patients  treated  at  the  Otorhinolaryngology  Out-
atient  Clinic  of  this  institution  between  January  2005  and
une  2013.
The  study  included  all  patients  diagnosed  with  NKTLN,
elected  through  the  electronic  database  of  the  Pathology
epartment  of  this  institution.
The  study  was  approved  by  the  Research  Ethics  Commit-
ee,  opinion  No.  444,035  of  October  18,  2013.esults
he  results  of  the  study  were  shown  in  Table  1.
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Table  1  Results  of  the  study.
Patient EPS  MAB  ACS  RGS  ACM  PLO  HRA
Gender  Male  Male  Male  Female  Male  Female  Male
Age at  diagnosis  34  43  47  24  35  25  60
Ethnicity Mixed-race  Mixed-race  White  White  Mixed-race  White  White
Signs and
symptoms
Rhinorrhea/
epistaxis
Rhinorrhea/
peritonsillar
bulge/cervical
lymph  node
enlargement
Rhinorrhea/nasal
obstruction
Rhinorrhea/oronasal
ﬁstula
Rhinorrhea/nasal
obstruc-
tion/palatal
pain
Rhinorrhea/
epistaxis/nasal
mass
Rhinorrhea/nasal
ala  lesion
Time between
symptom  onset
and  diagnosis
1  Year 7  Months 6  Months 3  Months 2  Months 4  Months 3  Months
ATB cycles  prior  to
biopsy
>Five  >Five  >Five  Between  three
and  ﬁve
Between  three
and  ﬁve
>Five  Between  three
and  ﬁve
Number of  Bx Three  Five  Three  One  Two One  One
Affected sites Mucosa  nasal/soft
palate
Nasal  mucosa/eye
corner  skin/lymph
node
Nasal  mucosa Nasal  mucosa Nasal
mucosa/hard
palate/larynx
Mucosa  nasal Mucosa
nasal/Nasal  ala
skin
Site of  diagnosis  Nasal  mucosa  Eye  corner  skin  Nasal  mucosa  Palatal  mucosa  Palatal  mucosa  Nasal  mucosa  Nasal
mucosa/nasal  ala
skin
EBV Positive  Negative  Positive  Negative  Positive  Negative  Positive
EBV in  bone
marrow
Negative  Negative  Negative  Negative  Negative  Negative  Negative
Human immunode-
ﬁciency
virus
Negative  Negative  Negative  Negative  Negative  Negative  Negative
Treatment RT  +  CT  Did  not  undergo  RT  +  CT  RT  +  CT  RT  +  CT  Undergoing
hematological
assessment
RT  +  CT
Survival 7  Years  (alive)  7  Months  Lost  to  follow-up  1  Year  and  2
months
3  Years  and  4
months  (alive)
5  Months  (alive)  6  Months  (alive)
Evolution Cured;  recurrence
in 2011.  Scheduled
for BMT
Invasive  fungal
rhinosinusitis  and
death
Lost  to  follow-up  Recurrence  after
11 months  and
death.
Laryngeal
recurrence  after  2
years.  New  CT
cycle.
Patient  newly
diagnosed.
Two  episodes  of
febrile
neutropenia.
Sequelae Oronasal
ﬁstula/necrosis  of
nasal  pyramid
Death  Oronasal  ﬁstula  Oronasal
ﬁstula/death
Oronasal  ﬁstula  Nasal  pyramid
necrosis
Nasal  ala
necrosis/hard
palate  inﬁltrate
EBV, Epstein--Barr virus; RT, radiotherapy; CT, chemotherapy; BMT, bone marrow transplantation.
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iscussion
he  differences  and  similarities  in  presentation,  diagnosis,
reatment  and  outcome  of  documented  clinical  cases  repre-
ent  a  diversiﬁed  overview  of  clinical-otorhinolaryngological
spects  of  NKTLN.
Of  the  seven  patients  (Table  1),  ﬁve  were  adult  males  and
our  were  between  34  and  47  years,  resembling  the  patient
roﬁle  more  often  observed  in  the  literature.1,2 However,
one  had  Asian  or  Amerindian  ancestry.
The  initial  clinical  picture  included  at  least  one  sinonasal
ymptom  in  all  cases  (rhinorrhea/nasal  obstruction)  and
atients  were  treated  with  antibiotics  for  the  treatment
f  acute  rhinosinusitis.  This  situation  delays  the  diagno-
is  and  treatment  of  patients  with  NKTLN  who,  in  general,
nly  undergo  biopsy  after  several  antibiotic  treatments.  In
he  present  series,  the  time  between  symptom  onset  and
he  histopathological  diagnosis  of  NKTLN  ranged  between  2
onths  and  1  year.
As  the  indication  for  the  biopsy  is  postponed,  the  evolu-
ion  of  NKTLN  shows  an  increase  in  the  amount  of  edema,
rusting,  bone  erosion,  and  necrosis  in  the  sinonasal  mucosa,
mpairing  the  histopathological  diagnosis  in  the  presence  of
ittle  signiﬁcant  samples  of  disease-affected  tissue.1 Thus,
he  earlier  the  biopsy  is  performed,  the  greater  the  chance
f  obtaining  a  representative  disease  sample,  reducing  the
umber  of  required  biopsies9 The  diagnoses  within  3  months
f  the  onset  of  symptoms  in  patients  RGS,  ACM,  and  HRA
as  attained  with  one  or  two  biopsies.  In  the  patients,  who
ad  symptoms  for  6  months  or  more,  three  or  more  biopsies
ere  necessary.
Sometimes,  due  to  the  prevalence  of  necrotic  tissues,
nd  secondary  infection  in  the  nasal  cavity,  depending  on
he  manner  in  which  the  lymphoma  spreads,  the  NKTLN  diag-
osis  may  be  achieved  by  a  biopsy  of  other  disease  sites,
uch  as  the  palate  and  skin,  which  we  noted  in  patients
AB,  RGS,  and  ACM.  Dissemination  to  other  organs  is  atypical
nd  may  involve  the  lungs,  gastrointestinal  tract,  kidneys,
ancreas,  testes,  and  brain,  in  addition  to  the  skin.1,2 Even
arer  is  a  primary  initial  presentation  of  NKTLN  outside  the
idfacial  region;  when  this  occurs,  it  usually  involves  the
kin.1,2
Another  problem  caused  by  the  presence  of  necrosis  and
rusting  of  the  nasal  mucosa  is  the  predisposition  to  sec-
ndary  infections,  especially  by  fungi.  This  condition  can  be
 confounding  factor  in  the  interpretation  of  the  histopatho-
ogical  examination,  leading  to  a  misdiagnosis  of  isolated
ungal  infection  in  a  patient  who  actually  has  NKTLN  with
econdary  fungal  infection.  Additionally,  secondary  infec-
ion  can  signiﬁcantly  worsen  the  prognosis  of  patients  with
KTLN  by  worsening  the  patient’s  clinical  condition,  and
ecause  it  is  a  condition  that  contraindicates  chemotherapy
dministration.1
Patient  MAB  underwent  biopsies  on  four  different  occa-
ions,  in  different  sites,  always  with  presence  of  Mucor  and
ecrosis  in  the  histopathological  diagnosis.  As  the  antifun-
al  treatment  had  shown  only  partial  improvement  and  a
ew  lesion  had  appeared  at  the  corner  of  the  eye,  this  site
as  chosen  for  the  ﬁfth  biopsy,  which  diagnosed  NKTLN.
owever,  as  the  patient  was  already  weakened  clinically,
hemotherapy  could  not  be  initiated  and  the  patient  died
uring  hospitalization.
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The  presence  of  EBV  in  tissue  biopsy  analysis  was  posi-
ive  in  four  of  the  seven  patients.  The  association  between
BV  and  NKTLN  has  been  well  established  in  the  literature,
lthough  its  mechanism  of  action  is  still  being  studied.4,5,10
t  is  also  believed  that  the  EBV  viral  load  may  be  a  progno-
tic  factor  in  the  evolution  of  NKTLN.4,10 The  presence  of
BV  was  not  detected  in  bone  marrow  and  no  patient  was
IV  positive.
Currently,  there  is  no  standardized  treatment  proto-
ol  for  NKTLN,  and  the  combination  of  radiotherapy  and
hemotherapy  is  routinely  used.1 All  our  patients  were
reated  in  this  manner,  except  MAB,  who  died  before  treat-
ent,  and  PLO,  who  had  been  newly  diagnosed.  Another
herapeutic  possibility  currently  being  investigated  is  bone
arrow  transplantation;  patient  EPS  has  been  scheduled  to
ndergo  this  procedure.
The  most  common  sequelae  observed  in  the  patients
ere  oronasal  ﬁstulas,  present  in  four  patients.  A  ﬁfth
atient  (HRA)  had  an  inﬁltrative  lesion  in  the  hard  palate,
ith  probable  progression  to  ﬁstula.  Of  the  other  two
emaining  patients,  one  was  newly  diagnosed  (PLO)  and  the
ther  showed  rapid  disease  progression,  leading  to  death
MAB).  Another  frequently  observed  sequela  was  nasal  pyra-
id  involvement,  observed  in  three  patients.  Two  patients
ad  complications:  MAB  had  invasive  fungal  rhinosinusitis
ven  before  the  diagnosis  of  NKTLN,  and  HRA  had  two
pisodes  of  febrile  neutropenia.  Two  patients  had  extra-
asal  involvement:  ACM,  laryngeal;  and  MAB,  eye  corner  skin
nd  cervical  lymph  node.  In  the  literature,  the  extra-nasal
anifestation  of  NKTLN  is  seen  in  one  in  every  three  to  four
atients.10
As  for  disease  evolution  and  behavior,  the  patients  stud-
ed  had  varied  characteristics.  MAB  had  an  evolution  of  only
 months  between  symptom  onset  and  death,  whereas  EPS
emains  alive  7  years  after  symptom  onset,  in  spite  of  a
ate-onset  diagnosis  (only  after  1 year  of  symptom  onset)
nd  after  tumor  recurrence  in  the  nasal  cavity.  In  addition
o  EPS,  two  other  patients  also  had  recurrence:  RGS  had
umor  recurrence  in  the  nasal  cavity  and  died;  and  ACM
ad  tumor  recurrence  in  the  larynx  and  underwent  a  new
hemotherapy  cycle.  In  general,  NKTLN  has  a  poor  outcome,
ith  overall  5-year  survival  ranging  from  20  to  65%.10--12
onclusion
lthough  rare,  the  diagnosis  of  NKTLN  should  always  be
onsidered  in  cases  of  repeated  rhinosinusitis  refractory  to
edical  treatment.  The  otolaryngologist  plays  a  fundamen-
al  role  in  the  prognosis  of  this  disease,  and  may  shorten  the
ime  between  symptom  onset  and  start  of  treatment  through
n  appropriate  clinical  history  that  precedes  biopsies.  Fur-
hermore,  it  is  also  important  to  perform  the  removal  of
ecrotic  tissue  in  the  nasal  cavity,  preventing  opportunis-
ic  infections  and  allowing  the  patient  to  be  submitted
o  radiation  therapy  and  chemotherapy  in  good  clinical
ondition.onﬂicts of  interest
he  authors  declare  no  conﬂicts  of  interest.
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